Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AVR
Upturn stock ratingUpturn stock rating

Anteris Technologies Global Corp. Common Stock (AVR)

Upturn stock ratingUpturn stock rating
$3.92
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: AVR (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

4 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $16.5

1 Year Target Price $16.5

Analysts Price Target For last 52 week
$16.5 Target price
52w Low $2.34
Current$3.92
52w High $8.79

Analysis of Past Performance

Type Stock
Historic Profit -29.91%
Avg. Invested days 5
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 287.16M USD
Price to earnings Ratio -
1Y Target Price 16.5
Price to earnings Ratio -
1Y Target Price 16.5
Volume (30-day avg) 4
Beta 0.74
52 Weeks Range 2.34 - 8.79
Updated Date 05/15/2025
52 Weeks Range 2.34 - 8.79
Updated Date 05/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.98

Earnings Date

Report Date 2025-08-14
When After Market
Estimate -0.53
Actual -0.5777

Profitability

Profit Margin -
Operating Margin (TTM) -2678.44%

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -840.17%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 279733221
Price to Sales(TTM) 101.59
Enterprise Value 279733221
Price to Sales(TTM) 101.59
Enterprise Value to Revenue 103.18
Enterprise Value to EBITDA -
Shares Outstanding 35939800
Shares Floating 17135301
Shares Outstanding 35939800
Shares Floating 17135301
Percent Insiders 7.63
Percent Institutions 45.17

ai summary icon Upturn AI SWOT

Anteris Technologies Global Corp. Common Stock

stock logo

Company Overview

overview logo History and Background

Anteris Technologies (ANTE) is a structural heart company focused on developing DurAVRu2122, a transcatheter heart valve (THV) addressing unmet needs in aortic stenosis. Founded in Australia, it has shifted its focus to the US market.

business area logo Core Business Areas

  • Structural Heart Solutions: Development and commercialization of DurAVRu2122, a novel transcatheter aortic valve replacement (TAVR) device.

leadership logo Leadership and Structure

The company is led by a management team focused on innovation and has a board of directors with expertise in medical devices. Details on specific individuals can be found in their annual reports and investor presentations.

Top Products and Market Share

overview logo Key Offerings

  • DurAVRu2122: DurAVRu2122 is a transcatheter heart valve (THV) designed to treat aortic stenosis. It aims to improve upon existing TAVR technologies with a unique single-piece design mimicking a natural valve. Competitors include Edwards Lifesciences (EW) and Medtronic (MDT). Market share is currently zero as the product is still in clinical trials and not yet commercially available. Potential market share depends on clinical trial outcomes and regulatory approvals.

Market Dynamics

industry overview logo Industry Overview

The structural heart market, particularly the TAVR segment, is experiencing significant growth due to an aging population and increasing adoption of minimally invasive procedures. Key players are constantly innovating to improve device performance and expand indications.

Positioning

Anteris Technologies aims to differentiate itself with DurAVRu2122, which is designed to offer improved hemodynamics and durability compared to existing TAVR devices. Success depends on positive clinical trial results and regulatory approvals.

Total Addressable Market (TAM)

The global TAVR market is projected to reach billions of USD annually. Anteris's position relative to this TAM depends on the successful commercialization of DurAVRu2122. Failure to get market approval could mean zero market share.

Upturn SWOT Analysis

Strengths

  • Novel DurAVRu2122 technology with potential for improved performance
  • Focus on unmet needs in aortic stenosis treatment
  • Experienced management team
  • Intellectual property protection for DurAVRu2122

Weaknesses

  • No currently approved products
  • Reliance on successful clinical trial outcomes
  • High R&D expenses
  • Limited financial resources compared to larger competitors
  • Negative Earnings history.

Opportunities

  • Growing TAVR market
  • Potential for expanded indications for DurAVRu2122
  • Strategic partnerships
  • Acquisition by a larger medical device company

Threats

  • Competition from established players (EW, MDT)
  • Regulatory hurdles and delays
  • Unsuccessful clinical trials
  • Technological advancements by competitors
  • Patent infringement litigation

Competitors and Market Share

competitor logo Key Competitors

  • EW
  • MDT
  • BSX

Competitive Landscape

Anteris Technologies faces stiff competition from established players with extensive resources and existing TAVR products. Its success hinges on demonstrating superior clinical outcomes with DurAVRu2122.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by preclinical and clinical development activities, rather than revenue growth.

Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of DurAVRu2122. Analyst estimates vary depending on the perceived likelihood of success.

Recent Initiatives: Recent initiatives include enrolling patients in clinical trials and presenting clinical data at medical conferences.

Summary

Anteris Technologies is a high-risk, high-reward investment. Its future relies heavily on the success of DurAVRu2122 and positive clinical trial results. The company needs to carefully manage its cash burn rate and navigate the regulatory landscape effectively. While there are many threats, the company has the ability to disrupt a growing market, if it can successfully commercialize DurAVR.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings (10-K, 10-Q)
  • Company Website
  • Investor Presentations
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in Anteris Technologies carries significant risk due to its development-stage nature.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Anteris Technologies Global Corp. Common Stock

Exchange NASDAQ
Headquaters Toowong, QLD, Australia
IPO Launch date 2024-12-13
Vice Chairman & CEO Mr. Wayne Geoffrey Paterson
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 136
Full time employees 136

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.